EQ
NASDAQ
$2.47
Equillium Inc (EQ)
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory or immuno-inflammatory disorders with unmet medical needs. The company is headquartered in La Jolla, California.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $8.56 (+246.56%)
Market Cap
$166M
Free Cash Flow Yield
-11.42%
Beta (5Y)
0.75
Price Chart
Valuation
Market Cap$166M
Forward P/E1.53
P/S20.22
P/B2.92
Profitability
Gross Profit (TTM)$4.39M
EBITDA-$20M
EPS-$0.38
Financial Health
Free Cash Flow Yield-11.42%
Growth & Risk
EPS 5Y CAGR-22.00%
FCF 5Y CAGR-6.43%
Beta (5Y)0.75
Sharpe Ratio1.74